Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials

Bernard Combe, Frank Behrens, Neil McHugh, Fiona Brock, Urs Kerkmann, Blerina Kola and Gaia Gallo
The Journal of Rheumatology May 2016, jrheum.151290; DOI: https://doi.org/10.3899/jrheum.151290
Bernard Combe
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Frank Behrens
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil McHugh
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fiona Brock
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Urs Kerkmann
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Blerina Kola
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gaia Gallo
From the Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University, Montpellier, France; CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology, Frankfurt am Main, Germany; Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath, Bath; Statistical Consultancy, Quanticate, Hitchin; Pfizer United Kingdom, Tadworth, UK; Pfizer Europe, Rome, Italy. Sponsored by Pfizer. Dr. Combe, Dr. Behrens, and Dr. McHugh have received honoraria and research grants from Pfizer. Ms. Brock was paid by Pfizer to provide statistical input to the study and manuscript. Dr. Kerkmann was a former employee of Pfizer. Drs. Kola and Gallo are employees of Pfizer. B. Combe, MD, Rheumatology Department, Lapeyronie Hospital, Montpellier 1 University; F. Behrens, MD, CIRI/Rheumatology, Goethe-University and Fraunhofer IME, Translational Medicine and Pharmacology; N. McHugh, MD, Royal National Hospital for Rheumatic Diseases and Department of Pharmacy and Pharmacology, University of Bath; F. Brock, MSc, Statistical Consultancy, Quanticate; U. Kerkmann, MD, former employee of Pfizer Europe; B. Kola, MD, Pfizer United Kingdom; G. Gallo, MD, Pfizer Europe. Address correspondence to Dr. B. Combe, Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen G. Giraud, 34295 Montpellier Cedex 5, France. E-mail: b-combe@chu-montpellier.fr. Accepted for publication February 26, 2016.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters
Next
Loading
Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 50, Issue 1
1 Jan 2023
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials
Bernard Combe, Frank Behrens, Neil McHugh, Fiona Brock, Urs Kerkmann, Blerina Kola, Gaia Gallo
The Journal of Rheumatology May 2016, jrheum.151290; DOI: 10.3899/jrheum.151290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials
Bernard Combe, Frank Behrens, Neil McHugh, Fiona Brock, Urs Kerkmann, Blerina Kola, Gaia Gallo
The Journal of Rheumatology May 2016, jrheum.151290; DOI: 10.3899/jrheum.151290
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • One-Third of European Patients with Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment
  • Oral Antiviral Treatment for COVID-19 in Patients With Systemic Autoimmune Rheumatic Diseases
  • The Positive Predictive Value of a Very High Serum IgG4 Concentration for the Diagnosis of IgG4-Related Disease
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire